Skip to content
Exits and Outcomes
Sign In
Subscribe
Digital health research, news, and analysis from Brian Dolan.
$200/year or
consider an Enterprise subscription
.
Prescription Digital Therapeutics
All Newsletters
214 articles
21 of 22
Trouble in Pear-adise? More details on ESI’s digital formulary.
9.27.19
8
min. Read
Excerpts from the Pear Therapeutics Report.
9.13.19
2
min. Read
Novartis predicts Amazon DTx delivery. VR pain relief.
8.22.19
5
min. Read
Samsung’s quiet CardioBand FDA clearance. HealthXL’s evidence report.
8.08.19
4
min. Read
CPT vs drug reimbursement pathways. Cancer DTx enforcement discretion.
8.01.19
5
min. Read
The case against Proteus-Otsuka’s digital med. AliveCor’s 6th CEO
7.25.19
4
min. Read
FDA Pre-Cert tested with Pear insomnia DTx.
7.18.19
7
min. Read
Germany passes DTx formulary, payment law. Outcomes over Exits?
7.11.19
6
min. Read
Digital health formulary wars heat up. $40M price tag for a digital drug.
6.20.19
7
min. Read
Express Scripts talks but CVS launches. India’s 4,800 health startups.
6.13.19
4
min. Read
1 of 22